Multiple Myeloma Clinical Trial

Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Summary

This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplantation.

View Full Description

Full Description

PRIMARY OBJECTIVE:

I. To determine whether escalating maintenance therapy with the addition of ixazomib citrate (ixazomib) to lenalidomide improves overall survival among patients who are MRD positive after approximately 1 year of lenalidomide maintenance following an early stem cell transplant (=< 12 months from diagnosis).

SECONDARY OBJECTIVES:

I. To establish whether progression-free survival is superior with the addition of ixazomib to lenalidomide maintenance.

II. To evaluate best response on treatment and compare response rates between arms.

III. To evaluate the safety profile of ixazomib added to lenalidomide and compare toxicity rates between arms.

EXPLORATORY CLINICAL OBJECTIVES:

I. To measure treatment exposure and adherence. II. To estimate treatment duration, duration of response and time to progression.

PATIENT-REPORTED OUTCOMES OBJECTIVES:

I. To determine the extent and timing of neuropathy associated with the addition of ixazomib to lenalidomide maintenance on patient reported health-related quality of life outcomes.

II. To assess the impact and timing of disease control with the addition of ixazomib to lenalidomide maintenance on patient reported health-related quality of life outcomes.

III. To evaluate attributes of select patient reported treatment-emergent symptomatic adverse events (Patient-Reported Outcomes - Common Terminology Criteria for Adverse Events [PRO-CTCAE]) longitudinally and compare responses with provider-reported adverse events.

IV. To measure the likelihood of medication adherence and examine the relationship with treatment exposure.

V. To assess correlation among patient reported outcome measures and association with clinical outcomes.

VI. To tabulate PRO compliance and completion rates.

IMAGING OBJECTIVES:

I. To evaluate the association between baseline fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT) and patient outcomes.

II. To compare overall survival (OS) with the addition of ixazomib to lenalidomide among baseline 18F-FDG PET/CT-positive and 18F-FDG PET/CT -negative subgroups.

III. To compare the change in quantitative 18F-FDG PET/CT parameters over time with the addition of ixazomib to lenalidomide.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive lenalidomide orally (PO) once daily (QD) on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months if < 2 years from study entry, every 6 months if 2-5 years from study entry, then every 12 months for up to 10 years from study entry.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

STEP 0: PRE-REGISTRATION
Patient must be previously diagnosed with multiple myeloma (MM) and be on lenalidomide maintenance with >= 10mg daily dose (>= 5 mg for patients with creatinine clearance 30-60 mL/min) for at least 10 months and no more than 15 months after an early autologous stem cell transplantation (SCT =< 12 months of diagnosis). Patient must not be off lenalidomide maintenance therapy for more than 30 days prior to start of treatment on Step 1 of this protocol
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

Patients must be able to undergo a diagnostic bone marrow aspirate following registration to Step 0

NOTE: A bone marrow aspirate specimen must be submitted to Mayo Clinic Hematology Laboratory for central assessment of minimal residual disease (MRD) status to confirm patient's eligibility for Step 1 randomization. Mayo Clinic will forward results =< within three (3) business days of receipt of the bone marrow specimen to the submitting institution
Patients must not have primary refractory or progressive disease on a proteasome inhibitor-based regimen during induction therapy prior to stem cell transplant

Patients must not be on other concurrent chemotherapy, or any ancillary therapy considered investigational

NOTE: Bisphosphonates are considered to be supportive care rather than therapy and are allowed while on protocol treatment
Patients must not have uncontrolled psychiatric illness or social situations that would limit compliance with study requirements
Patients must not have another malignancy requiring treatment or have received treatment within 2 years before pre-registration or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
Patients must have been able to maintain at least 10 mg dose of lenalidomide without growth factor support (at least 5 mg for patients with creatinine clearance 30-60 mL/min)
Patients must not have known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or lenalidomide including difficulty swallowing
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
Patients must not have known hepatitis B surface antigen-positive status or known or suspected active hepatitis C infection, but testing specifically for the trial is not required
STEP 1 RANDOMIZATION
Patient must meet Step 0 eligibility criteria at the time of Step 1 randomization
Patient must not be off lenalidomide maintenance therapy for more than 30 days prior to start of treatment on Step 1 of this protocol
Patients must have evidence of residual disease by central MRD testing or by presence of monoclonal protein in serum or urine

Serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and serum free light chain (FLC) performed =< 28 days prior to randomization

NOTE: UPEP (on a 24-hour collection) is required, no substitute method is acceptable. Urine must be followed monthly if the baseline urine M-spike is >= 200 mg/24 hour (hr). Please note that if both serum and urine M-components are present, both must be followed in order to evaluate response
Hemoglobin >= 8 g/dL (obtained =< 14 days prior to randomization)
Untransfused platelet count >= 75,000 cells/mm^3 (obtained =< 14 days prior to randomization)
Absolute neutrophil count >= 1000 cells/mm^3 (obtained =< 14 days prior to randomization)
Calculated creatinine clearance >= 30 mL/min (obtained =< 14 days prior to randomization)
Total bilirubin =< 1.5 times the upper limit of normal (obtained =< 14 days prior to randomization)
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) and serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 times the upper limit of normal (obtained =< 14 days prior to randomization)
Patients must not have grade 2 or higher peripheral neuropathy or grade 1 peripheral neuropathy with pain per CTCAE
Patients must not have uncontrolled intercurrent illness
Patients must not have grade 2 or higher diarrhea per CTCAE in the absence of antidiarrheals
Patients must not have been on systemic treatment, within 14 days before the first dose of ixazomib, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort
Patient must agree to register into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program and be willing and able to comply with the requirements of Revlimid REMS
Patient must not be pregnant due to potential harm to the fetus from ixazomib and lenalidomide. All patients of childbearing potential must have a blood test or urine study with a sensitivity of at least 25 mIU/mL within 10-14 days prior to the first dose of lenalidomide and again within 24 hours prior to the first dose of lenalidomide. Patients of childbearing potential must also agree to ongoing pregnancy testing while on treatment. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Patients of childbearing potential must either abstain from sexual intercourse for the duration of their participation in the study or agree to use TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME for 1) at least 28 days before starting study treatment; 2) while participating in the study; 3) during dose interruptions; and 4) for at least 90 days after the last dose of protocol treatment. Patients must also agree to not breastfeed during this same time period. Men must agree to either abstain from sexual intercourse for the duration of their participation in the study or use a latex condom during sexual contact with a partner of childbearing potential while participating in the study and for 90 days after the last dose of protocol treatment even if they have had a successful vasectomy. Patients must also agree to abstain from donating sperm while on study treatment and for 28 days after the last dose of protocol treatment even if they have had a successful vasectomy. All patients must agree to abstain from donating blood during study participation and for at least 28 days after the last dose of protocol treatment

Study is for people with:

Multiple Myeloma

Phase:

Phase 3

Estimated Enrollment:

510

Study ID:

NCT03941860

Recruitment Status:

Recruiting

Sponsor:

National Cancer Institute (NCI)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 184 Locations for this study

See Locations Near You

Cancer Center at Saint Joseph's
Phoenix Arizona, 85004, United States
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs Arkansas, 71913, United States
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande California, 93420, United States
Pacific Central Coast Health Center-San Luis Obispo
San Luis Obispo California, 93401, United States
Mission Hope Medical Oncology - Santa Maria
Santa Maria California, 93444, United States
Penrose-Saint Francis Healthcare
Colorado Springs Colorado, 80907, United States
Rocky Mountain Cancer Centers-Penrose
Colorado Springs Colorado, 80907, United States
Porter Adventist Hospital
Denver Colorado, 80210, United States
Mercy Medical Center
Durango Colorado, 81301, United States
Southwest Oncology PC
Durango Colorado, 81301, United States
Saint Anthony Hospital
Lakewood Colorado, 80228, United States
Littleton Adventist Hospital
Littleton Colorado, 80122, United States
Longmont United Hospital
Longmont Colorado, 80501, United States
Rocky Mountain Cancer Centers-Longmont
Longmont Colorado, 80501, United States
Parker Adventist Hospital
Parker Colorado, 80138, United States
Saint Mary Corwin Medical Center
Pueblo Colorado, 81004, United States
Rush - Copley Medical Center
Aurora Illinois, 60504, United States
Illinois CancerCare-Bloomington
Bloomington Illinois, 61704, United States
Illinois CancerCare-Canton
Canton Illinois, 61520, United States
Memorial Hospital of Carbondale
Carbondale Illinois, 62902, United States
SIH Cancer Institute
Carterville Illinois, 62918, United States
Illinois CancerCare-Carthage
Carthage Illinois, 62321, United States
Centralia Oncology Clinic
Centralia Illinois, 62801, United States
Carle on Vermilion
Danville Illinois, 61832, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Suparna Mantha
Principal Investigator
Cancer Care Specialists of Illinois - Decatur
Decatur Illinois, 62526, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Decatur Memorial Hospital
Decatur Illinois, 62526, United States
Illinois CancerCare-Dixon
Dixon Illinois, 61021, United States
Carle Physician Group-Effingham
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Suparna Mantha
Principal Investigator
Crossroads Cancer Center
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Eureka
Eureka Illinois, 61530, United States
Illinois CancerCare-Galesburg
Galesburg Illinois, 61401, United States
Western Illinois Cancer Treatment Center
Galesburg Illinois, 61401, United States
Illinois CancerCare-Kewanee Clinic
Kewanee Illinois, 61443, United States
Illinois CancerCare-Macomb
Macomb Illinois, 61455, United States
Carle Physician Group-Mattoon/Charleston
Mattoon Illinois, 61938, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Suparna Mantha
Principal Investigator
Cancer Care Center of O'Fallon
O'Fallon Illinois, 62269, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Ottawa Clinic
Ottawa Illinois, 61350, United States
Illinois CancerCare-Pekin
Pekin Illinois, 61554, United States
Illinois CancerCare-Peoria
Peoria Illinois, 61615, United States
Methodist Medical Center of Illinois
Peoria Illinois, 61636, United States
Illinois CancerCare-Peru
Peru Illinois, 61354, United States
Valley Radiation Oncology
Peru Illinois, 61354, United States
Illinois CancerCare-Princeton
Princeton Illinois, 61356, United States
Southern Illinois University School of Medicine
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
217-545-7929
Bryan A. Faller
Principal Investigator
Springfield Clinic
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
800-444-7541
Bryan A. Faller
Principal Investigator
Memorial Medical Center
Springfield Illinois, 62781, United States
Carle Cancer Center
Urbana Illinois, 61801, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Suparna Mantha
Principal Investigator
The Carle Foundation Hospital
Urbana Illinois, 61801, United States
Illinois CancerCare - Washington
Washington Illinois, 61571, United States
Rush-Copley Healthcare Center
Yorkville Illinois, 60560, United States
Mary Greeley Medical Center
Ames Iowa, 50010, United States More Info
Site Public Contact
Contact
515-956-4132
Debra M. Prow
Principal Investigator
McFarland Clinic PC - Ames
Ames Iowa, 50010, United States More Info
Site Public Contact
Contact
515-239-4734
[email protected]
Debra M. Prow
Principal Investigator
McFarland Clinic PC-Boone
Boone Iowa, 50036, United States More Info
Site Public Contact
Contact
515-956-4132
Debra M. Prow
Principal Investigator
Saint Anthony Regional Hospital
Carroll Iowa, 51401, United States
Medical Oncology and Hematology Associates-West Des Moines
Clive Iowa, 50325, United States
Mercy Cancer Center-West Lakes
Clive Iowa, 50325, United States
Alegent Health Mercy Hospital
Council Bluffs Iowa, 51503, United States
Greater Regional Medical Center
Creston Iowa, 50801, United States
Iowa Methodist Medical Center
Des Moines Iowa, 50309, United States More Info
Site Public Contact
Contact
515-241-6727
Joshua Lukenbill
Principal Investigator
Medical Oncology and Hematology Associates-Des Moines
Des Moines Iowa, 50309, United States More Info
Site Public Contact
Contact
515-241-3305
Joshua Lukenbill
Principal Investigator
Broadlawns Medical Center
Des Moines Iowa, 50314, United States More Info
Site Public Contact
Contact
515-282-2200
Joshua Lukenbill
Principal Investigator
Mercy Medical Center - Des Moines
Des Moines Iowa, 50314, United States
Mission Cancer and Blood - Laurel
Des Moines Iowa, 50314, United States
Iowa Lutheran Hospital
Des Moines Iowa, 50316, United States
McFarland Clinic PC-Trinity Cancer Center
Fort Dodge Iowa, 50501, United States More Info
Site Public Contact
Contact
515-956-4132
Debra M. Prow
Principal Investigator
Trinity Regional Medical Center
Fort Dodge Iowa, 50501, United States
McFarland Clinic PC-Jefferson
Jefferson Iowa, 50129, United States More Info
Site Public Contact
Contact
515-956-4132
Debra M. Prow
Principal Investigator
McFarland Clinic PC-Marshalltown
Marshalltown Iowa, 50158, United States More Info
Site Public Contact
Contact
515-956-4132
Debra M. Prow
Principal Investigator
Methodist West Hospital
West Des Moines Iowa, 50266, United States
Mercy Medical Center-West Lakes
West Des Moines Iowa, 50266, United States
Cancer Center of Kansas-Wichita Medical Arts Tower
Wichita Kansas, 67208, United States More Info
Site Public Contact
Contact
316-268-5374
[email protected]
Shaker R. Dakhil
Principal Investigator
Ascension Via Christi Hospitals Wichita
Wichita Kansas, 67214, United States More Info
Site Public Contact
Contact
800-362-0070
[email protected]
Shaker R. Dakhil
Principal Investigator
Cancer Center of Kansas - Wichita
Wichita Kansas, 67214, United States More Info
Site Public Contact
Contact
316-268-5374
[email protected]
Shaker R. Dakhil
Principal Investigator
Flaget Memorial Hospital
Bardstown Kentucky, 40004, United States
Commonwealth Cancer Center-Corbin
Corbin Kentucky, 40701, United States
Saint Joseph Radiation Oncology Resource Center
Lexington Kentucky, 40504, United States
Saint Joseph Hospital East
Lexington Kentucky, 40509, United States
Saint Joseph London
London Kentucky, 40741, United States
Jewish Hospital
Louisville Kentucky, 40202, United States
Saints Mary and Elizabeth Hospital
Louisville Kentucky, 40215, United States
UofL Health Medical Center Northeast
Louisville Kentucky, 40245, United States
Jewish Hospital Medical Center South
Shepherdsville Kentucky, 40165, United States
Tufts Medical Center
Boston Massachusetts, 02111, United States More Info
Site Public Contact
Contact
617-636-5000
[email protected]
Raymond L. Comenzo
Principal Investigator
Saint Joseph Mercy Hospital
Ann Arbor Michigan, 48106, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Christopher M. Reynolds
Principal Investigator
University of Michigan Comprehensive Cancer Center
Ann Arbor Michigan, 48109, United States More Info
Site Public Contact
Contact
800-865-1125
Jing C. Ye
Principal Investigator
Bronson Battle Creek
Battle Creek Michigan, 49017, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Saint Joseph Mercy Brighton
Brighton Michigan, 48114, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Christopher M. Reynolds
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton Michigan, 48114, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Christopher M. Reynolds
Principal Investigator
Saint Joseph Mercy Canton
Canton Michigan, 48188, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Christopher M. Reynolds
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton Michigan, 48188, United States More Info
Site Public Contact
Contact
734-712-7251
MCRCweb[email protected]
Christopher M. Reynolds
Principal Investigator
Saint Joseph Mercy Chelsea
Chelsea Michigan, 48118, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Christopher M. Reynolds
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea Michigan, 48118, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Christopher M. Reynolds
Principal Investigator
Ascension Saint John Hospital
Detroit Michigan, 48236, United States More Info
Site Public Contact
Contact
313-343-3166
[email protected]
Christopher M. Reynolds
Principal Investigator
Great Lakes Cancer Management Specialists-Doctors Park
East China Township Michigan, 48054, United States More Info
Site Public Contact
Contact
313-343-3166
[email protected]
Christopher M. Reynolds
Principal Investigator
Genesee Cancer and Blood Disease Treatment Center
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Christopher M. Reynolds
Principal Investigator
Genesee Hematology Oncology PC
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Christopher M. Reynolds
Principal Investigator
Genesys Hurley Cancer Institute
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Christopher M. Reynolds
Principal Investigator
Mercy Health Saint Mary's
Grand Rapids Michigan, 49503, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Spectrum Health at Butterworth Campus
Grand Rapids Michigan, 49503, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Academic Hematology Oncology Specialists
Grosse Pointe Woods Michigan, 48236, United States More Info
Site Public Contact
Contact
313-343-3166
[email protected]
Christopher M. Reynolds
Principal Investigator
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Grosse Pointe Woods Michigan, 48236, United States More Info
Site Public Contact
Contact
313-343-3166
[email protected]
Christopher M. Reynolds
Principal Investigator
Bronson Methodist Hospital
Kalamazoo Michigan, 49007, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
West Michigan Cancer Center
Kalamazoo Michigan, 49007, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Ascension Borgess Cancer Center
Kalamazoo Michigan, 49009, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia Michigan, 48154, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Christopher M. Reynolds
Principal Investigator
Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb Michigan, 48044, United States More Info
Site Public Contact
Contact
313-343-3166
[email protected]
Christopher M. Reynolds
Principal Investigator
Mercy Health Mercy Campus
Muskegon Michigan, 49444, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Cancer and Hematology Centers of Western Michigan - Norton Shores
Norton Shores Michigan, 49444, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Spectrum Health Reed City Hospital
Reed City Michigan, 49677, United States More Info
Site Public Contact
Contact
616-391-1230
crcwm-regulator[email protected]
Kathleen J. Yost
Principal Investigator
Marie Yeager Cancer Center
Saint Joseph Michigan, 49085, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Bhadresh Nayak MD PC-Sterling Heights
Sterling Heights Michigan, 48312, United States More Info
Site Public Contact
Contact
313-343-3166
[email protected]
Christopher M. Reynolds
Principal Investigator
Munson Medical Center
Traverse City Michigan, 49684, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Great Lakes Cancer Management Specialists-Macomb Professional Building
Warren Michigan, 48093, United States More Info
Site Public Contact
Contact
313-343-3166
[email protected]
Christopher M. Reynolds
Principal Investigator
Macomb Hematology Oncology PC
Warren Michigan, 48093, United States More Info
Site Public Contact
Contact
313-343-3166
[email protected]
Christopher M. Reynolds
Principal Investigator
Saint John Macomb-Oakland Hospital
Warren Michigan, 48093, United States More Info
Site Public Contact
Contact
313-343-3166
[email protected]
Christopher M. Reynolds
Principal Investigator
Metro Health Hospital
Wyoming Michigan, 49519, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Huron Gastroenterology PC
Ypsilanti Michigan, 48106, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Christopher M. Reynolds
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti Michigan, 48197, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Christopher M. Reynolds
Principal Investigator
Sanford Joe Lueken Cancer Center
Bemidji Minnesota, 56601, United States More Info
Site Public Contact
Contact
218-333-5000
[email protected]
Preston D. Steen
Principal Investigator
Fairview Ridges Hospital
Burnsville Minnesota, 55337, United States
Minnesota Oncology - Burnsville
Burnsville Minnesota, 55337, United States
Cambridge Medical Center
Cambridge Minnesota, 55008, United States
Mercy Hospital
Coon Rapids Minnesota, 55433, United States
Fairview Southdale Hospital
Edina Minnesota, 55435, United States
Unity Hospital
Fridley Minnesota, 55432, United States
Fairview Clinics and Surgery Center Maple Grove
Maple Grove Minnesota, 55369, United States
Minnesota Oncology Hematology PA-Maplewood
Maplewood Minnesota, 55109, United States
Saint John's Hospital - Healtheast
Maplewood Minnesota, 55109, United States
Abbott-Northwestern Hospital
Minneapolis Minnesota, 55407, United States
Hennepin County Medical Center
Minneapolis Minnesota, 55415, United States
Health Partners Inc
Minneapolis Minnesota, 55454, United States
Monticello Cancer Center
Monticello Minnesota, 55362, United States
New Ulm Medical Center
New Ulm Minnesota, 56073, United States
Fairview Northland Medical Center
Princeton Minnesota, 55371, United States
North Memorial Medical Health Center
Robbinsdale Minnesota, 55422, United States
Mayo Clinic in Rochester
Rochester Minnesota, 55905, United States More Info
Site Public Contact
Contact
855-776-0015
Prashant Kapoor
Principal Investigator
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park Minnesota, 55416, United States
Regions Hospital
Saint Paul Minnesota, 55101, United States
United Hospital
Saint Paul Minnesota, 55102, United States
Saint Francis Regional Medical Center
Shakopee Minnesota, 55379, United States
Lakeview Hospital
Stillwater Minnesota, 55082, United States
Ridgeview Medical Center
Waconia Minnesota, 55387, United States
Rice Memorial Hospital
Willmar Minnesota, 56201, United States
Minnesota Oncology Hematology PA-Woodbury
Woodbury Minnesota, 55125, United States
Fairview Lakes Medical Center
Wyoming Minnesota, 55092, United States
Saint Francis Medical Center
Cape Girardeau Missouri, 63703, United States More Info
Site Public Contact
Contact
573-334-2230
[email protected]
Bryan A. Faller
Principal Investigator
Southeast Cancer Center
Cape Girardeau Missouri, 63703, United States
Parkland Health Center - Farmington
Farmington Missouri, 63640, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Capital Region Southwest Campus
Jefferson City Missouri, 65109, United States
Missouri Baptist Medical Center
Saint Louis Missouri, 63131, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Mercy Hospital Saint Louis
Saint Louis Missouri, 63141, United States More Info
Site Public Contact
Contact
314-251-7066
Jay W. Carlson
Principal Investigator
Sainte Genevieve County Memorial Hospital
Sainte Genevieve Missouri, 63670, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Missouri Baptist Sullivan Hospital
Sullivan Missouri, 63080, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Missouri Baptist Outpatient Center-Sunset Hills
Sunset Hills Missouri, 63127, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
CHI Health Saint Francis
Grand Island Nebraska, 68803, United States
CHI Health Good Samaritan
Kearney Nebraska, 68847, United States
Saint Elizabeth Regional Medical Center
Lincoln Nebraska, 68510, United States
Alegent Health Immanuel Medical Center
Omaha Nebraska, 68122, United States
Alegent Health Bergan Mercy Medical Center
Omaha Nebraska, 68124, United States
Alegent Health Lakeside Hospital
Omaha Nebraska, 68130, United States
Creighton University Medical Center
Omaha Nebraska, 68131, United States
Midlands Community Hospital
Papillion Nebraska, 68046, United States
Sanford Bismarck Medical Center
Bismarck North Dakota, 58501, United States More Info
Site Public Contact
Contact
701-323-5760
[email protected]
Preston D. Steen
Principal Investigator
Sanford Broadway Medical Center
Fargo North Dakota, 58122, United States More Info
Site Public Contact
Contact
701-323-5760
[email protected]
Preston D. Steen
Principal Investigator
Sanford Roger Maris Cancer Center
Fargo North Dakota, 58122, United States More Info
Site Public Contact
Contact
701-234-6161
[email protected]
Preston D. Steen
Principal Investigator
Strecker Cancer Center-Belpre
Belpre Ohio, 45714, United States More Info
Site Public Contact
Contact
800-523-3977
[email protected]
Timothy D. Moore
Principal Investigator
Miami Valley Hospital South
Centerville Ohio, 45459, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Adena Regional Medical Center
Chillicothe Ohio, 45601, United States More Info
Site Public Contact
Contact
877-779-7585
[email protected]
Timothy D. Moore
Principal Investigator
Good Samaritan Hospital - Cincinnati
Cincinnati Ohio, 45220, United States
Bethesda North Hospital
Cincinnati Ohio, 45242, United States
TriHealth Cancer Institute-Westside
Cincinnati Ohio, 45247, United States
TriHealth Cancer Institute-Anderson
Cincinnati Ohio, 45255, United States
Mount Carmel East Hospital
Columbus Ohio, 43213, United States More Info
Site Public Contact
Contact
614-488-2118
[email protected]
Timothy D. Moore
Principal Investigator
Columbus Oncology and Hematology Associates Inc
Columbus Ohio, 43214, United States More Info
Site Public Contact
Contact
614-488-2118
[email protected]
Timothy D. Moore
Principal Investigator
Riverside Methodist Hospital
Columbus Ohio, 43214, United States More Info
Site Public Contact
Contact
614-566-4475
[email protected]
Timothy D. Moore
Principal Investigator
Grant Medical Center
Columbus Ohio, 43215, United States More Info
Site Public Contact
Contact
614-566-4475
[email protected]
Timothy D. Moore
Principal Investigator
The Mark H Zangmeister Center
Columbus Ohio, 43219, United States More Info
Site Public Contact
Contact
614-488-2118
[email protected]
Timothy D. Moore
Principal Investigator
Mount Carmel Health Center West
Columbus Ohio, 43222, United States More Info
Site Public Contact
Contact
614-234-5433
[email protected]
Timothy D. Moore
Principal Investigator
Doctors Hospital
Columbus Ohio, 43228, United States More Info
Site Public Contact
Contact
614-566-3275
[email protected]
Timothy D. Moore
Principal Investigator
Miami Valley Hospital
Dayton Ohio, 45409, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Miami Valley Hospital North
Dayton Ohio, 45415, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Delaware Health Center-Grady Cancer Center
Delaware Ohio, 43015, United States More Info
Site Public Contact
Contact
740-615-0227
[email protected]
Timothy D. Moore
Principal Investigator
Grady Memorial Hospital
Delaware Ohio, 43015, United States More Info
Site Public Contact
Contact
740-615-2403
[email protected]
Timothy D. Moore
Principal Investigator
Dublin Methodist Hospital
Dublin Ohio, 43016, United States
Atrium Medical Center-Middletown Regional Hospital
Franklin Ohio, 45005, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Central Ohio Breast and Endocrine Surgery
Gahanna Ohio, 43230, United States
Mount Carmel Grove City Hospital
Grove City Ohio, 43123, United States
Fairfield Medical Center
Lancaster Ohio, 43130, United States More Info
Site Public Contact
Contact
740-687-8863
[email protected]
Timothy D. Moore
Principal Investigator
Saint Rita's Medical Center
Lima Ohio, 45801, United States
OhioHealth Mansfield Hospital
Mansfield Ohio, 44903, United States
Marietta Memorial Hospital
Marietta Ohio, 45750, United States More Info
Site Public Contact
Contact
800-523-3977
[email protected]
Timothy D. Moore
Principal Investigator
OhioHealth Marion General Hospital
Marion Ohio, 43302, United States More Info
Site Public Contact
Contact
614-488-2118
[email protected]
Timothy D. Moore
Principal Investigator
Knox Community Hospital
Mount Vernon Ohio, 43050, United States More Info
Site Public Contact
Contact
740-393-9000
[email protected]
Timothy D. Moore
Principal Investigator
Licking Memorial Hospital
Newark Ohio, 43055, United States More Info
Site Public Contact
Contact
740-348-4000
[email protected]
Timothy D. Moore
Principal Investigator
Newark Radiation Oncology
Newark Ohio, 43055, United States
Mercy Health Perrysburg Cancer Center
Perrysburg Ohio, 43551, United States
Southern Ohio Medical Center
Portsmouth Ohio, 45662, United States More Info
Site Public Contact
Contact
614-488-2118
[email protected]
Timothy D. Moore
Principal Investigator
Saint Vincent Mercy Medical Center
Toledo Ohio, 43608, United States
Mercy Health - Saint Anne Hospital
Toledo Ohio, 43623, United States
Upper Valley Medical Center
Troy Ohio, 45373, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Saint Ann's Hospital
Westerville Ohio, 43081, United States More Info
Site Public Contact
Contact
614-234-5433
[email protected]
Timothy D. Moore
Principal Investigator
Genesis Healthcare System Cancer Care Center
Zanesville Ohio, 43701, United States More Info
Site Public Contact
Contact
740-454-5232
[email protected]
Timothy D. Moore
Principal Investigator
University of Oklahoma Health Sciences Center
Oklahoma City Oklahoma, 73104, United States More Info
Site Public Contact
Contact
405-271-8777
[email protected]
Mohamad Khawandanah
Principal Investigator
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa Oklahoma, 74146, United States More Info
Site Public Contact
Contact
918-505-3200
Mohamad Khawandanah
Principal Investigator
Penn State Milton S Hershey Medical Center
Hershey Pennsylvania, 17033, United States More Info
Site Public Contact
Contact
717-531-3779
[email protected]
Kevin Rakszawski
Principal Investigator
Tidelands Georgetown Memorial Hospital
Georgetown South Carolina, 29440, United States
Sanford Cancer Center Oncology Clinic
Sioux Falls South Dakota, 57104, United States More Info
Site Public Contact
Contact
605-312-3320
[email protected]
Preston D. Steen
Principal Investigator
Sanford USD Medical Center - Sioux Falls
Sioux Falls South Dakota, 57117, United States More Info
Site Public Contact
Contact
605-312-3320
[email protected]
Preston D. Steen
Principal Investigator
Saint Joseph Regional Cancer Center
Bryan Texas, 77802, United States
Harrison Medical Center
Bremerton Washington, 98310, United States
Highline Medical Center-Main Campus
Burien Washington, 98166, United States
Saint Elizabeth Hospital
Enumclaw Washington, 98022, United States
Saint Francis Hospital
Federal Way Washington, 98003, United States
Saint Clare Hospital
Lakewood Washington, 98499, United States
Franciscan Research Center-Northwest Medical Plaza
Tacoma Washington, 98405, United States
ThedaCare Regional Cancer Center
Appleton Wisconsin, 54911, United States More Info
Site Public Contact
Contact
920-364-3605
[email protected]
Matthias Weiss
Principal Investigator
Mayo Clinic Health System-Franciscan Healthcare
La Crosse Wisconsin, 54601, United States More Info
Site Public Contact
Contact
855-776-0015
Prashant Kapoor
Principal Investigator
ProHealth D N Greenwald Center
Mukwonago Wisconsin, 53149, United States More Info
Site Public Contact
Contact
[email protected]
Timothy R. Wassenaar
Principal Investigator
Cancer Center of Western Wisconsin
New Richmond Wisconsin, 54017, United States
ProHealth Oconomowoc Memorial Hospital
Oconomowoc Wisconsin, 53066, United States More Info
Site Public Contact
Contact
262-928-7878
Timothy R. Wassenaar
Principal Investigator
ProHealth Waukesha Memorial Hospital
Waukesha Wisconsin, 53188, United States More Info
Site Public Contact
Contact
262-928-7632
Timothy R. Wassenaar
Principal Investigator
UW Cancer Center at ProHealth Care
Waukesha Wisconsin, 53188, United States More Info
Site Public Contact
Contact
262-928-5539
[email protected]
Timothy R. Wassenaar
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 3

Estimated Enrollment:

510

Study ID:

NCT03941860

Recruitment Status:

Recruiting

Sponsor:


National Cancer Institute (NCI)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.